MENU

GANX Stock Tickeron detected bullish Stock Pattern: Cup-and-Handle GANX on September 16, 2024, netting in a 25.94% gain over 1 week

A.I.dvisor
at Tickeron.com
09/28/24
Loading...
+25.94% Gain from a Successful pattern Cup-and-Handle
GANX - Gain Therapeutics
Ticker: GANX
Company: Gain Therapeutics
Gain: +25.94%
Confirmed: 09/16/24
Succeeded: 09/26/24
Total length: 13 days
On September 13, 2024, A.I.dvisor detected a Cup-and-Handle Pattern (Bullish) for Gain Therapeutics (GANX, $1.47). On September 16, 2024, A.I.dvisor confirmed the Bullish pattern, setting a target price of $1.91. 10 days later, on September 26, 2024, GANX reached the target price resulting in a +2 for traders who took a long position in the stock.

GANX in upward trend: 10-day moving average broke above 50-day moving average on September 12, 2024

The 10-day moving average for GANX crossed bullishly above the 50-day moving average on September 12, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 11, 2024. You may want to consider a long position or call options on GANX as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GANX just turned positive on September 11, 2024. Looking at past instances where GANX's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .

GANX moved above its 50-day moving average on September 10, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where GANX advanced for three days, in of 167 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 63 cases where GANX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GANX moved out of overbought territory on October 08, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GANX broke above its upper Bollinger Band on October 07, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 70%.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GANX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.836) is normal, around the industry mean (12.550). P/E Ratio (0.000) is within average values for comparable stocks, (110.042). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.002). GANX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (625.000) is also within normal values, averaging (222.739).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
GANX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
4800 Montgomery Lane
Phone
+1 301 500-1556
Employees
32
Web
https://www.gaintherapeutics.com